Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General business news Salasar Techno Engineering posts 23.5% revenue growth in Q3 FY25 Salasar Techno Engineering Limited delivered a robust financial performance in the third quarter of fiscal year 2025, reporting… byPallavi MadhirajuFebruary 15, 2025